


STATUS OF THE CLAIMS

1. (currently amended) A compound having Formula I:



or a pharmaceutically acceptable salt or ~~prodrug~~ thereof, wherein:

R₁ is C₁₋₂ alkyl or C₁₋₂ haloalkyl;

R₂ is branched or unbranched alkyl or cycloalkyl or substituted or unsubstituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl;

X is CONH, CH₂O, CH₂NH, CH₂S, or (CH₂)₁₋₃;

Y₁ is (CH₂)₁₋₅, wherein one or more carbon can be replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen, and one or more hydrogens in CH₂ groups can be replaced by a branched or unbranched alkyl or cyclic alkyl or substituted or unsubstituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl;







Y₂ is (CH₂)₁₋₅, wherein one or more carbon can be replaced by one or more heteroatoms selected from oxygen, sulfur, and nitrogen, and one or more hydrogens in CH₂ groups can be replaced by a branched or unbranched alkyl or cyclic alkyl or substituted or unsubstituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl; and








Z is CONH, CH₂O, NHCO, (CH₂)₁₋₄, (CH₂)₁₋₃CONH(CH₂)₀₋₃, (CH₂)₁₋₃S(CH₂)₀₋₃, (CH₂)₁₋₃NH(CH₂)₀₋₃, (CH₂)₁₋₃NHCO(CH₂)₀₋₃, (CH₂)₁₋₃NHSO₂(CH₂)₀₋₃, (CH₂)₁₋₃NHC(O)NH(CH₂)₀₋₃, (CH₂)₁₋₃NHC(S)NH(CH₂)₀₋₃, (CH₂)₁₋₃NR'(CH₂)₀₋₃, wherein R' is branched or unbranched alkyl or cycloalkyl or substituted or unsubstituted aryl, alkylaryl, heteroaryl, or alkylheteroaryl.








2. (Original) The compound of claim 1, wherein X is CONH.







3. (Original) The compound of claim 1, wherein Z is CONH.



4. (Original) The compound of claim 1, wherein X and Z are CONH.
5. (Original) The compound of claim 1, wherein said compound is selected from the group consisting of:







































6. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
7. (Original) The pharmaceutical composition of claim 6, wherein X is CONH.
8. (Original) The pharmaceutical composition of claim 6, wherein Z is CONH.
9. (Original) The pharmaceutical composition of claim 6, wherein X and Z are CONH.
10. (Original) The pharmaceutical composition of claim 6, wherein said compound is selected from the group consisting of:











11. - 35. (canceled)

36. (Original) A kit comprising a compound of claim 1 and instructions for administering said compound to an animal.

37. (Original) The kit of claim 36, further comprising an inducer of apoptosis.

38. (Original) The kit of claim 37, wherein said inducer of apoptosis is a chemotherapeutic agent.
39. (Original) The kit of claim 36, wherein said instructions are for administering said compound to an animal having a hyperproliferative disease.
40. (Original) The kit of claim 39, wherein said hyperproliferative disease is cancer.